{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:41:32Z","timestamp":1766580092615},"reference-count":25,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1536\/ihj.13-322","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T23:26:16Z","timestamp":1399418776000},"page":"213-218","source":"Crossref","is-referenced-by-count":11,"title":["Stent Thrombosis in Patients With Coronary Artery Disease Treated With Biodegradable Polymer Drug-Eluting Stents"],"prefix":"10.1536","volume":"55","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fifth People\u2019 Hospital of Dalian"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013; 368: 254-65. (Review)","DOI":"10.1056\/NEJMra1210816"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60324-9"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.049"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2011.05.025"},{"key":"5","unstructured":"5. Lupi A, Rognoni A, Secco GG, <i>et al<\/i>. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a metaanalysis of 5834 patients. Eur J Prev Cardiol (in press)"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV3I5A103"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Byrne RA, Kufner S, Tiroch K, <i>et al<\/i>; ISAR-TEST-3 investigators. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary stenosis: 2-year follow-up results. Heart 2009; 95: 1489-94.","DOI":"10.1136\/hrt.2009.172379"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Guagliumi G, Sirbu V, Musumeci G, <i>et al<\/i>. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable albuminal polymer: Optimal Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI). Circ Cardiovasc Interv 2010; 3: 367-75.","DOI":"10.1161\/CIRCINTERVENTIONS.110.950154"},{"key":"12","unstructured":"12. Li Q, Wang LF, Yang XC, <i>et al<\/i>. Efficacy comparison of primary coronary intervention with biodegradable polymer- and durable polymer-based sirolimus-eluting stents for patients with acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 2010; 38: 886-90. (Chinese)"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Byrne RA, Kastrati A, Massberg S, <i>et al<\/i>; ISAR-TEST 4 Investiagors. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011; 58: 1325-31.","DOI":"10.1016\/j.jacc.2011.06.027"},{"key":"14","unstructured":"14. Xu B, Dou KF, Han YL, <i>et al<\/i>. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical followup results. Chin Med J 2011; 124: 811-6."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Xu B, Dou KF, Yang Y, <i>et al<\/i>. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA 1 trial. EuroIntervention 2012; 8: 796-802.","DOI":"10.4244\/EIJV8I7A122"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Serruys PW, Farooq V, Kalesan B, <i>et al<\/i>. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimuseluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv 2013; 6: 777-89.","DOI":"10.1016\/j.jcin.2013.04.011"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gao RL, Xu B, Lansky AJ, <i>et al<\/i>; TARGET I Investigators. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention 2013; 9: 75-83.","DOI":"10.4244\/EIJV9I1A12"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61962-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Natsuaki M, Kozuma K, Morimoto T, <i>et al<\/i>; NEXT Investigators. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol 2013; 62: 181-90.","DOI":"10.1016\/j.jacc.2013.04.045"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61852-2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Zhang Y, Shen J, Li Z, <i>et al<\/i>. Two-year clinical outcomes of different drug-eluting stents with different polymer coating strategies in coronary artery heart disease: a multi-centre, randomised, controlled clinical trial. Int J Cardiol 2013; 168: 2646-52.","DOI":"10.1016\/j.ijcard.2013.03.034"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2011.10.013"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Rodriguez-Granillo A, Rubilar B, Rodriguez-Granillo G, Rodriguez AE. Advantages and disadvantages of biodegradable platforms in drug eluting stents. World J Cardiol 2011; 3: 84-92.","DOI":"10.4330\/wjc.v3.i3.84"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Park SJ, Park DW, Kim YH, <i>et al<\/i>. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-82.","DOI":"10.1056\/NEJMoa1001266"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs086"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/55\/3\/55_13-322\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T23:34:37Z","timestamp":1618616077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/55\/3\/55_13-322\/_article"}},"subtitle":["An Update Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.13-322","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}